Deletion of the high-density lipoprotein receptor scavenger receptor BI in mice modulates thrombosis susceptibility and indirectly affects platelet function by elevation of plasma free cholesterol

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 1, 2011, Pages 34-42

  Korporaal, Suzanne J A ^a   Meurs, Illiana ^a   Hauer, Arnaud D ^a   Hildebrand, Reeni B ^a   Hoekstra, Menno ^a   Ten Cate, Hugo ^b   Praticò, Domenico ^c   Akkerman, Jan Willem N ^d   Van Berkel, Theo J C ^a   Kuiper, Johan ^a   Van Eck, Miranda ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

arterial thrombosis; HDL; platelets; SR BI

Indexed keywords

FERRIC CHLORIDE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN RECEPTOR; SCAVENGER RECEPTOR BI;

ANIMAL EXPERIMENT; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE PREDISPOSITION; GENE DELETION; HOMEOSTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE SHAPE; THROMBOCYTOPENIA;

ANIMALS; ARTERIAL OCCLUSIVE DISEASES; BLOOD PLATELETS; BONE MARROW TRANSPLANTATION; CHLORIDES; CHOLESTEROL, DIETARY; CHOLESTEROL, HDL; DISEASE MODELS, ANIMAL; FERRIC COMPOUNDS; FIBRINOGEN; MICE; MICE, KNOCKOUT; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION; SCAVENGER RECEPTORS, CLASS B; THROMBOCYTOPENIA; THROMBOSIS; TIME FACTORS; UP-REGULATION;

EID: 78650866717     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.210252     Document Type: Article

References (51)

1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8:1227-1234.
2. Rosenson RS, Lowe GD. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis. 1998;140:271-280.
3. Griffin JH, Fernández JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost. 2001;86:386-394.
4. Assinger A, Schmid W, Eder S, Schmid D, Koller E, Volf I. Oxidation by hypochlorite converts protective HDL into a potent platelet agonist. FEBS Lett. 2008;582:778-784.
5. Nofer JR, Walter M, Kehrel B, Wierwille S, Tepel M, Seedorf U, Assmann G. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide- derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler Thromb Vasc Biol. 1998;18: 861-869.
6. Chen LY, Mehta JL. Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. Life Sci. 1994;55:1815-1821.
7. Nofer JR, Walter M, Kehrel B, Seedorf U, Assmann G. HDL3 activates phospholipase D in normal but not glycoprotein IIb/IIIa-deficient platelets. Biochem Biophys Res Commun. 1995;207:148-154.
8. Nazih H, Nazih-Sanderson F, Magret V, Caron B, Goudemand J, Fruchart JC, Delbart C. Protein kinase C-dependent desensitization of HDL3-activated phospholipase C in human platelets. Arterioscler Thromb. 1994; 14:1321-1326.
9. Vergani CG, Plancher AC, Zuin M, Cattaneo M, Tramaloni C, Maccari S, Roma P, Catapano AL. Bile lipid composition and haemostatic variables in a case of high density lipoprotein deficiency (Tangier disease). Eur J Clin Invest. 1984;14:49-54.
10. Naqvi TZ. Shah PK, Ivey PA, Molloy MD, Thomas AM, Panicker S, Ahmed A, Cercek B, Kaul S. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol. 1999;84:1011-1017.
11. Acton S, Rigotti A, Landschultz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271:518-520.
12. Gu X, Kozarsky K, Krieger M. Scavenger receptor class B, type I-mediated [3H]cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor. J Biol Chem. 2000;275: 29993-30001.
13. Greaves DR, Gough PJ, Gordon S. Recent progress in defining the role of scavenger receptors in lipid transport, atherosclerosis and host defence. Curr Opin Lipidol. 1998;9:425-432.
14. Landschulz KT, Pathak RK, Rigotti A, Krieger M, Hobbs HH. Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J Clin Invest. 1996;98: 984-995.
15. Out R, Hoekstra M, Spijkers JA, Kruijt JK, Van Eck M, Bos IS, Twisk J, Van Berkel TJ. Scavenger receptor class B type I is solely responsible for the selective uptake of cholesteryl esters from HDL by the liver and the adrenals in mice. J Lipid Res. 2004;45:2088.
16. Stangl H, Hyatt M, Hobbs HH. Transport of lipids from high and low density lipoproteins via scavenger receptor-BI. J Biol Chem. 1999;274: 32692-32698.
17. Yeh YC, Hwang GY, Liu IP, Yang VC. Identification and expression of scavenger receptor SR-BI in endothelial cells and smooth muscle cells of rat aorta in vitro and in vivo. Atherosclerosis. 2002;161:95-103.
18. Hirano K, Yamashita S, Nakagawa Y, Ohya T, Matsuura F, Tsukamoto K, Okamoto Y, Matsuyama A, Matsumoto K, Miyagawa J, Matsuzawa Y. Expression of human scavenger receptor class B type I in cultured human monocyte-derived macrophages and atherosclerotic lesions. Circ Res. 1999;85:108-116.
19. Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P, Chapman J, Fruchart JC, Tedgui A, Najib-Fruchart J, Staels B. CLA- 1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation. 2000;101:2411-2417.
20. Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci USA. 1997;94: 12610-12615.
21. Van Eck M, Twisk J, Hoekstra M, Van Rij BT, Van der Lans CA, Bos IS, Kruijt JK, Kuipers F, Van Berkel TJ. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J Biol Chem. 2003;278:23699-23705.
22. Trigatti B, Rayburn H, Vinals M, Braun A, Miettinen H, Penman M, Hertz M, Schrenzel M, Amigo L, Rigotti A, Krieger M. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci USA. 1999;96:9322-9327.
23. Miettinen HE, Rayburn H, Krieger M. Abnormal lipoprotein metabolism and reversible female infertility in HDL receptor (SR-BI)-deficient mice. J Clin Invest. 2001;108:1717-1722.
24. Meurs I, Hoekstra M, van Wanrooij EJ, Hildebrand RB, Kuiper J, Kuipers F, Hardeman MR, Van Berkel TJ, Van Eck M. HDL cholesterol levels are an important factor for determining the lifespan of erythrocytes. Exp Hematol. 2005;33:1309-1319.
25. Holm TM, Braun A, Trigatti BL, Brugnara C, Sakamoto M, Krieger M, Andrews NC. Failure of red blood cell maturation in mice with defects in the high-density lipoprotein receptor SR-BI. Blood. 2002;99:1817-1824.
26. Braun A, Trigatti BL, Post MJ, Sato K, Simons M, Edelberg JM, Rosenberg RD, Schrenzel M, Krieger M. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res. 2002;90: 270-276.
27. Imachi H, Murao K, Cao W, Tada S, Taminato T, Wong NC, Takahara J, Ishida T. Expression of human scavenger receptor B1 on and in human platelets. Arterioscler Thromb Vasc Biol. 2003;23:898-904.
28. Dole VS, Matuskova J, Vasile E, Yesilaltay A, Bergmeier W, Bernimoulin M, Wagner DD, Krieger M. Thrombocytopenia and platelet abnormalities in high-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2008;28:1111-1116.
29. Cadigan KM, Spillane DM, Chang T. Isolation and characterization of chinese hasmter ovary cell mutants defective in intracellular low density lipoprotein-cholesterol trafficking. J Biol Chem. 1990;110:295-308.
30. Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2003;23:712-719.
31. Farrehi PM, Ozaki CK, Carmeliet P, Fay WP. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation. 1998;97:1002-1008.
32. Praticò D, Cyrus T, Li H, FitzGerald GA. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood. 2000;96:3823-3826.
33. Reilly M, FitzGerald GA. Cellular activation by thromboxane A2 and other eicosanoids. Eur Heart J. 1993;14:S88-S93.
34. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330: 1287-1294.
35. Van Eck M, Bos IS, Hildebrand RB, Van Rij BT, Van Berkel TJ. Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. Am J Pathol. 2004;165:785-794.
36. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res. 1990;60:269-280.
37. Hartwig JH, Barkalow K, Azim A, Italiano J. The elegant platelet: signals controlling actin assembly. Thromb Haemost. 1999;82:392-398.
38. Bodin S, Tronchère H, Payrastre B. Lipid rafts are critical membrane domains in blood platelet activation processes. Biochim Biophys Acta. 2003;1610:247-257.
39. Heijnen HF, Van Lier M, Waaijenborg S, Ohno-Iwashita Y, Waheed AA, Inomata M, Gorter G, Möbius W, Akkerman JW, Slot JW. Concentration of rafts in platelet filopodia correlates with recruitment of c-Src and CD63 to these domains. J Thromb Haemost. 2003;1:1161-1173.
40. Lindon JN, Kushner L, Salzman EW. Platelet interaction with artificial surfaces: in vitro evaluation. Methods Enzymol. 1989;169:104-117.
41. Mineo C, Shaul PW. Role of high-density lipoprotein and scavenger receptor B type I in the promotion of endothelial repair. Trends Cardiovasc Med. 2007;17:156-161.
42. Betteridge DJ, Cooper MD, Saggerson ED, Prichard BN, Tan KC, Ling E, Barbera G, McCarthy S, Smith CC. Platelet function in patients with hypercholesterolaemia. Eur J Clin Invest. 1994;24: 30-33.
43. Davi G, Gresele P, Violi F, Basili S, Catalano M, Giammarresi C, Volpato R, Nenci GG, Ciabattoni G, Patrono C. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation. 1997;96:69-75.
44. Van Lier M, Verhoef S, Cauwenberghs S, Heemskerk JW, Akkerman JW, Heijnen HF. Role of membrane cholesterol in platelet calcium signaling in response to VWF and collagen under stasis and flow. Thromb Haemost. 2008;99:1068-1078.
45. Brass LF, Hoxie JA, Manning DR. Signaling through G proteins and G protein-coupled receptors during platelet activation. Thromb Haemost. 1993;70:217-223.
46. Farndale RW, Slatter DA, Siljander PR, Jarvis GE. Platelet receptor recognition and cross-talk in collagen-induced activation of platelets. J Thromb Haemost. 2007;5:220-229.
47. Reed GL, Fitzgerald ML, Polgár J. Molecular mechanisms of platelet exocytosis: insights into the "secrete" life of thrombocytes. Blood. 2000; 96:3334-3342.
48. Barton JF, Hardy AR, Poole AW, Mundell SJ. Reciprocal regulation of platelet responses to P2Y and thromboxane receptor activation. J Thromb Haemost. 2008;6:534-543.
49. Santamarina-Fojo S, Hoeg JM, Assmann G, Brewer HB Jr. Lecithin cholesterol acyltransferase deficiency and fish eye disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001: 2817-2833.
50. Nordöy A, Gjone E. Familial plasma lecithin:cholesterol acyltransferase deficiency: a study of platelets. Scand J Clin Lab Invest. 1971;27: 263-268.
51. Harmon JT, Tandon NN, Hoeg JM, Jamieson GA. Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia. Blood. 1986; 68:498-505.